ArticleJournal of clinical neuromuscular disease2026
Development and Validation of the Inclusion Body Myositis-Health Index: A Disease-Specific Patient-Reported Outcome Measure for Use in Clinical Trials and Drug-Labeling Claims.
Article in Journal of clinical neuromuscular disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
objectivesAs novel therapeutic interventions are considered for individuals with inclusion body myositis (IBM), valid outcome measures are needed to quantify therapeutic gain and disease progression during clinical trials. To meet this need, we developed and validated the Inclusion Body Myositis-Health Index (IBM-HI), a regulatory-grade, disease-specific, patient-reported outcome measure capable of measuring a patient's perception of their point-in-time disease burden.
methodsWe conducted an international cross-sectional study where we asked participants with IBM about the most prevalent and impactful symptoms affecting their everyday lives. Symptoms identified in the cross-sectional survey were included in the first version of the IBM-HI. We subsequently used factor analysis, beta testing, test-retest reliability, and known groups analysis to validate, refine, and optimize the instrument.
resultsFive hundred and sixty-nine individuals with IBM completed a survey to identify what issues and symptoms are most important to include and measure in an IBM-specific outcome measure. Fifteen individuals with IBM beta tested the first version of the IBM-HI and 21 participants completed test-retest reliability testing at baseline and two weeks. Participants found the IBM-HI to be easy to use, comprehensive, and highly relevant to their condition. Each of the IBM-HI questions and all 13 subscales were found to be reliable over a 14-day period (intraclass correlation coefficient = 0.95). Known groups assessments determined that the IBM-HI and its subscales are able to differentiate between predefined clinical and demographic subgroups expected to experience higher or lower levels of disease burden.
conclusionsThe IBM-HI is a reliable comprehensive instrument capable of measuring a wide spectrum of symptoms experienced by individuals with IBM. This instrument adds to existing IBM clinical trial infrastructure and provides clinicians and researchers with a mechanism to quantify how patients feel and function in the context of a therapeutic trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.